Apparent diffusion coefficient measurements of the middle cerebellar peduncle differentiate the Parkinson variant of MSA from Parkinson's disease and progressive supranuclear palsy

被引:151
|
作者
Nicoletti, Giuseppe
Lodi, Raffaele
Condino, Francesca
Tonon, Caterina
Fera, Francesco
Malucelli, Emil
Manners, David
Zappia, Mario
Morgante, Letterio
Barone, Paolo
Barbiroli, Bruno
Quattrone, Aldo
机构
[1] Univ Bologna, Policlin S Orsola, Dipartimento Med Clin & Biotecnol Applicata D Cam, I-40138 Bologna, Italy
[2] CNR, Inst Neurol Sci, Mangone, Cosenza, Italy
[3] Policlin S Orsola, Dipartimento Area Radiol, Bologna, Italy
[4] Univ Magna Graecia, Inst Neurol, Catanzaro, Italy
[5] Univ Messina, Policlin Univ, Dept Neurosci Psychiat & Anesthesiol, I-98100 Messina, Italy
[6] Univ Naples Federico II, Dept Neurol Sci, Naples, Italy
关键词
diffusion imaging; middle cerebellar peduncle; multiple system atrophy; progressive supranuclear palsy; Parkinson's disease;
D O I
10.1093/brain/awl166
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Clinical differentiation of parkinsonian syndromes such as the Parkinson variant of multiple system atrophy (MSA-P) and progressive supranuclear palsy (PSP) from Parkinson's disease is difficult in the early stage of the disease. In order to identify objective markers for differential diagnosis, we studied these three groups of patients with diffusion-weighted MRI (DWI). Sixteen MSA-P patients, 16 with PSP, 16 with Parkinson's disease and 15 healthy volunteers were studied. Regional apparent diffusion coefficients (rADC) were determined in different brain regions including basal ganglia, thalamus, white matter, pons and middle cerebellar peduncles (MCPs). rADC calculated in the MCP completely differentiated MSA-P patients (median: 0.93 x 10(-3) mm(2)/s) from PSP patients (median: 0.82 x 10(-3) mm(2)/s, P < 0.001), Parkinson's disease patients (median: 0.79 x 10(-3) mm(2)/s, P < 0.001) and healthy volunteers (median: 0.81 x 10(-3) mm(2)/s, P < 0.001). Other regions considered showed an overlapping among groups. DWI discriminates MSA-P from PSP and Parkinson's disease and healthy volunteers on the basis of MCP rADC values. These in vivo results confirm the pathological findings that the majority of MSA-P patients have moderate or severe degenerative changes not only in the nigrostriatal but also in the olivopontocerebellar systems. Our findings indicate that, in order to substantially contribute to the in vivo differential diagnosis of MSA-P, PSP and Parkinson's disease, rADC measurements should not be limited to the basal ganglia but should also include the MCP.
引用
收藏
页码:2679 / 2687
页数:9
相关论文
共 50 条
  • [41] The applause sign and neuropsychological profile in progressive supranuclear palsy and Parkinson's disease
    Somme, Johanne
    Carlos Gomez-Esteban, Juan
    Tijero, Beatriz
    Berganzo, Koldo
    Lezcano, Elena
    Jose Zarranz, Juan
    CLINICAL NEUROLOGY AND NEUROSURGERY, 2013, 115 (08) : 1230 - 1233
  • [42] Combination of midbrain-to-pontine ratio and cardiac MIBG scintigraphy to differentiate Parkinson's disease from multiple system atrophy and progressive supranuclear palsy
    Sakuramoto, Hirotaka
    Fujita, Hiroaki
    Suzuki, Keisuke
    Matsubara, Takeo
    Watanabe, Yuji
    Hamaguchi, Mai
    Hirata, Koichi
    CLINICAL PARKINSONISM & RELATED DISORDERS, 2020, 2 : 20 - 24
  • [43] Clinical speech impairment in Parkinson's disease, progressive supranuclear palsy, and multiple system atrophy
    Sachin, S.
    Shukla, G.
    Goyal, V.
    Singh, S.
    Aggarwal, Vijay
    Gureshkumar
    Behari, M.
    NEUROLOGY INDIA, 2008, 56 (02) : 122 - 126
  • [44] Patterns of brain atrophy in Parkinson's disease, progressive supranuclear palsy and multiple system atrophy
    Messina, Demetrio
    Cerasa, Antonio
    Condino, Francesca
    Arabia, Gennarina
    Novellino, Fabiana
    Nicoletti, Giuseppe
    Salsone, Maria
    Morelli, Maurizio
    Lanza, Pier Luigi
    Quattrone, Aldo
    PARKINSONISM & RELATED DISORDERS, 2011, 17 (03) : 172 - 176
  • [45] Hypokinesia without decrement distinguishes progressive supranuclear palsy from Parkinson's disease
    Ling, Helen
    Massey, Luke A.
    Lees, Andrew J.
    Brown, Peter
    Day, Brian L.
    BRAIN, 2012, 135 : 1141 - 1153
  • [46] Quantifying Impairments in Swallowing Safety and Efficiency in Progressive Supranuclear Palsy and Parkinson’s Disease
    James C. Borders
    Jordanna S. Sevitz
    James A. Curtis
    Nora Vanegas-Arroyave
    Michelle S. Troche
    Dysphagia, 2023, 38 : 1342 - 1352
  • [47] Clinical Features of Patients with Concomitant Parkinson's Disease and Progressive Supranuclear Palsy Pathology
    Rigby, Heather B.
    Dugger, Brittany N.
    Hentz, Joseph G.
    Adler, Charles H.
    Beach, Thomas G.
    Shill, Holly A.
    Driver-Dunckley, Erika
    Sabbagh, Marwan N.
    Sue, Lucia I.
    Caviness, John N.
    MOVEMENT DISORDERS CLINICAL PRACTICE, 2015, 2 (01): : 33 - 38
  • [48] Comparison of gait in progressive supranuclear palsy, Parkinson’s disease and healthy older adults
    Thorlene Egerton
    David R Williams
    Robert Iansek
    BMC Neurology, 12
  • [49] Differentiating Progressive Supranuclear Palsy and Parkinson's Disease With Head-Mounted Displays
    Herwig, Arvid
    Agic, Almedin
    Huppertz, Hans-Jurgen
    Klingebiel, Randolf
    Zuhorn, Frederic
    Schneider, Werner X.
    Schaebitz, Wolf-Ruediger
    Rogalewski, Andreas
    FRONTIERS IN NEUROLOGY, 2021, 12
  • [50] Evidence for angiogenesis in Parkinson's disease, incidental Lewy body disease, and progressive supranuclear palsy
    Bradaric, Brinda Desai
    Patel, Aditiben
    Schneider, Julie A.
    Carvey, Paul M.
    Hendey, Bill
    JOURNAL OF NEURAL TRANSMISSION, 2012, 119 (01) : 59 - 71